{
  "source": "Cardiovascular-Disease-Prevention-Prior-Authorization.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2025 P 1213-9\nProgram Prior Authorization/Regulatory\nMedication Health Care Reform - Cardiovascular Disease Prevention Zero Cost\nShare - atorvastatin (generic Lipitor) 10 mg and 20 mg and simvastatin\n(generic Zocor) 5 mg, 10 mg, 20 mg, 40 mg\nP&T Approval Date 3/2017, 3/2018, 3/2019, 3/2020, 3/2021, 3/2022, 11/2022, 1/2024,\n3/2025\nEffective Date 6/1/2025\n1. Background:\nThe U.S. Preventive Services Task Force (USPSTF)1 recommends that clinicians engage in\nshared, informed decision making with patients who are at increased risk for cardiovascular\ndisease (CVD).\nThe USPSTF recommends that adults without a history of cardiovascular disease (CVD) (i.e.,\nmyocardial infarction or ischemic stroke) use a low- to moderate-dose statin for the\nprevention of CVD events and mortality when all of the following criteria are met: 1) they are\naged 40 to 75 years; 2) they have 1 or more CVD risk factors (i.e., dyslipidemia, diabetes,\nhypertension, or smoking); and 3) they have an estimated 10-year risk of a cardiovascular\nevent of 10% or greater. (http://tools.acc.org/ASCVD-Risk-estimator/)\nThis program is designed to evaluate whether or not members meet the primary prevention\ncriteria for obtaining coverage of low-to moderate-dose lipid lowering therapy (statins) at\nzero dollar cost share.\n2. Coverage Criteria:\nA. Upon request, coverage at zero dollar cost share will be approved based on all of the\nfollowing criteria:\n1. Member is between the ages of 40 and 75\n-AND-\n2. Medication is being used for primary prevention of CVD (i.e., member has no history\nof cardiovascular events)\n-AND-\n3. Member has one or more risk factors for CVD (i.e., dyslipidemia, diabetes,\nhypertension, or smoking)\n-AND-\n4. Member has an estimated 10-year risk of a cardiovascular event of 10% or greater\n© 2025 UnitedHealthcare Services Inc.\n1\nAuthorization will be issued for zero copay with deductible bypass for 24 months. If zero\ndollar cost share",
    "ear risk of a cardiovascular event of 10% or greater\n© 2025 UnitedHealthcare Services Inc.\n1\nAuthorization will be issued for zero copay with deductible bypass for 24 months. If zero\ndollar cost share criteria is not met the requested drug will default to plan coverage\nrequirements.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-\nauthorization based solely on previous claim/medication history, diagnosis codes (ICD-\n10) and/or claim logic. Use of automated approval and re-approval processes varies by\nprogram and/or therapeutic class.\n4. References:\n1. U.S. Preventive Services Task Force http://www.uspreventiveservicestaskforce.org/\nAccessed February 2025.\n2. Arnett DK, Blumenthal RS, Albert MA, et al. 2019 ACC/AHA Guideline on the primary\nprevention of cardiovascular disease: a report of the American College of\nCardiology/American Heart Association Task Force on Clinical Practice Guidelines.\nCirculation. 2019;140(11):e596-e646.\n3. ASCVD Risk Estimator Plus: http://tools.acc.org/ASCVD-Risk-estimator/\nProgram Prior Authorization/HCR- Cardiovascular Disease Prevention Copay\nReduction\nChange Control\nDate Change\n3/2017 New program.\n3/2018 Annual review. No changes.\n3/2019 Annual review. No changes.\n3/2020 Annual review. No changes.\n3/2021 Annual review. No changes.\n3/2022 Annual review. Added dyslipidemia definition to background.\n11/2022 Updated background to align with latest USPSTF recommendation\n(removed definition of dyslipidemia, replaced calculated risk with\nestimated risk, replaced symptomatic coronary artery disease with\nmyocardial infarction). Updated criteria to replace calculated risk with\nestimated risk. Updated references.\n1/2024 Annual review. Updated references. Revised criteria to add that review\nis upon request with no change to clinical intent.\n3/2025 Annual review. Updated references.\n© 2025 UnitedHealthcare Services Inc.\n2"
  ]
}